Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA) and maintenance therapy to prevent exacerbations by targeting underlying pathophysiology (e.g., a LABA/ICS, such as GSK’s Advair or AstraZeneca’s Symbicort); most pediatric asthma patients receive more than one agent to treat their condition. Despite the availability of multiple, well-established therapies, the pediatric asthma treatment landscape has seen the approval and launch of additional agents in recent years, including salmeterol / fluticasone generics and novel biological drugs (e.g., Regeneron / Sanofi’s Dupixent, GSK’s Nucala). These events have added more treatment options and fueled competition in this market.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric asthma patients?
- What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric asthma patients?
- How have newer biological therapies, such as AstraZeneca’s Fasenra, been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of pediatric asthma patients receive drug therapy within 365 days of diagnosis, and how quickly?
- What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of pediatric asthma patients are treated with monotherapy versus combination therapy?
- What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
- United States
Real world data
- Longitudinal patient-level claims data analysis
Key drugs covered:
- Advair, Symbicort, Dulera, Breo, Fasenra, Nucala, Xolair, Ventolin, ProAir, montelukast sodium, Flovent, Spiriva
Key analysis provided
- Brand/therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.